Market Overview

UPDATE: Credit Suisse Upgrades St. Jude Medical to Outperform on Durata Outlook

Share:
Related STJ
FireEye CTO Discusses Changes In The Cybersecurity Industry: 'We're Now Responsible For A Customer's Security Infrastructure'
Wall Street's M&A Chatter From November 15
Abbott Vs. Alere, Or Kramer Vs. Kramer (Seeking Alpha)

Credit Suisse upgraded St. Jude Medical (NYSE: STJ) from Neutral to Outperform and raised the price target from $43.00 to $48.00.

Credit Suisse noted, "Since Riata (STJ's recalled defib lead) failure reports began to circulate widely in 8/10, concerns about Durata's reliability (STJ's current defib lead) have weighed on STJ's valuation. While Durata concerns are likely to persist near-term, we came away from STJ's investor day impressed by the company's confidence in Durata and its optimism about the May HRS conference where STJ expects to see multiple favorable Durata studies."

St. Jude Medical closed at $41.17 on Friday.

Latest Ratings for STJ

DateFirmActionFromTo
Jul 2016WedbushDowngradesOutperformNeutral
Jul 2016Leerink SwannDowngradesOutperformMarket Perform
May 2016BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for STJ
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Analyst Ratings

 

Related Articles (STJ)

View Comments and Join the Discussion!